ASCO GI 2022

Oesophageal and Gastric Cancer

EMR versus ESD in oesophageal cancer

Presented By

Dr Vani Konda, Baylor University Medical Center, TX, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:23

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

Presented By

Prof. Karyn Goodman, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:22

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By

Dr Jiafu Ji, Beijing Cancer Hospital, China

Trial

Phase 1/2, AK104-201

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:19

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By

Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan

Trial

Phase 2, DESTINY-Gastric01

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:17

The emerging role of AI in gastroesophageal cancer

Presented By

Dr Wai Leung, University of Hong Kong, China

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:15

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1109, NExT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:13

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Trial

Phase 3, CheckMate 649, DELIVER

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:11

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:08

Anal and Colorectal Cancer

NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC

Presented By

Dr Romain Cohen, Sorbonne University, France

Trial

Phase 2, NIPICOL

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:30

Dostarlimab may offer an alternative for dMMR rectal cancer

Presented By

Dr Melissa Lumish, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:28

DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:26

Key updates in colorectal cancer screening

Presented By

Dr Robin Mendelsohn, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:25

Impact of COVID-19 on screening for colorectal cancer

Presented By

Dr John Carethers, University of Michigan, MI, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:23

Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Presented By

Dr Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 9X8

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:21

No benefit of additional oxaliplatin in elderly patients with mCRC

Presented By

Dr Tetsuya Hamaguchi, National Cancer Center, Japan

Trial

Phase 3, JCOG1018, RESPECT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:19

Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled

Presented By

Dr Claire Gallois, Université de Paris, France

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:17

Long-course chemoradiation versus short-course radiotherapy in rectal cancer

Presented By

Dr Emma Holliday, MD Anderson Cancer Center, University of Texas, TX, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:15

Analysis of metastasectomy in CRC reveals benefits and disparities

Presented By

Dr Jude Khatib (University of Texas, TX, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:12

EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo

Presented By

Dr William Harris, Seattle Cancer Care Alliance, WA, USA

Trial

Phase 3, EPOCH

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:09

Hepatobiliary Cancer

Adjuvant S-1 therapy superior to observation in resected biliary tract cancer

Presented By

Dr Masafumi Ikeda, Japan Clinical Oncology Group, Japan

Trial

Phase 3, JCOG1202, ASCOT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:13

Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Presented By

Prof. Shukui Qin, Nanjing University of Chinese Medicine, China

Trial

Phase 3, KEYNOTE-394

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:11

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer

Presented By

Dr Do-Youn Oh, Seoul National University College of Medicine, South Korea

Trial

Phase 3, TOPAZ-1

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:09

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By

Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA

Trial

Phase 3, HIMALAYA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:05

LAUNCH: TACE plus lenvatinib efficacious in advanced HCC

Presented By

Prof. Ming Kuang, Sun Yat-sen University, China

Trial

Phase 3, LAUNCH

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:03

Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC

Presented By

Dr Hyeyeong Kim, Ulsan University Hospital, South Korea

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:00

Pancreatic Cancer